Treatment of Parkinson disease: A 64-year-old man with motor complications of advanced Parkinson disease

JAMA

Volumn 307, Issue 21, 2012, Pages 2305-2314

  Tarsy, Daniel ^a  

^a National Parkinson Foundation Center of Excellence Parkinson Disease Center   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; APOMORPHINE; BENSERAZIDE; BENZATROPINE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LANSOPRAZOLE; LEVODOPA; LISURIDE; LORAZEPAM; MONOAMINE OXIDASE B INHIBITOR; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL;

ABNORMAL URINE COMPOSITION; ANXIETY; ARTHRALGIA; BLURRED VISION; BRADYKINESIA; BRAIN DEPTH STIMULATION; BRAIN HEMORRHAGE; BRAIN INFARCTION; COGNITIVE DEFECT; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DISEASE COURSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; FOREIGN BODY REACTION; GAIT DISORDER; GLOBUS PALLIDUS; HUMAN; INSOMNIA; INVOLUNTARY MOVEMENT; LIVEDO RETICULARIS; LIVER TOXICITY; MEMORY DISORDER; MENTAL DISEASE; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NAUSEA; NIGHTMARE; NOTE; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PSYCHOSIS; SIDE EFFECT; SUBTHALAMIC NUCLEUS; SURGICAL INFECTION; THALAMUS; TREMOR; URINE DISCOLORATION; URINE RETENTION; VISUAL HALLUCINATION; VOMITING; WALKING DIFFICULTY; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84861903821     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.4829     Document Type: Note

References (86)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5(6):525-535. (Pubitemid 44262284)
2. Fahn S. Parkinson's disease: 10 years of progress, 1997-2007. Mov Disord. 2010;25(suppl 1):S2-S14.
3. Rajput AH, Voll A, Rajput A, et al. Course in Parkinson's disease subtypes. Neurology. 2009;73(3):206-212.
4. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinicopathological study of subtypes in Parkinson's disease. Brain. 2009;132(pt 11):2947-2957.
5. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol. 2001;58(10):1611-1615. (Pubitemid 32963225)
6. Klawans HL. Individual manifestations of Parkinson's disease after ten or more years of levodopa. Mov Disord. 1986;1(3):187-192.
7. US Preventive Services Task Force Grade Definitions May 2008. http://www.uspreventiveservicestaskforce.org/uspstf/grades/htm. .
8. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord. 2008;23(suppl 3):S497-S508.
9. Goetz CG. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology. 1990;40(10)(suppl 3):50-54.
10. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001;56(11)(suppl 5):S1-S88. (Pubitemid 32532291)
11. Parkinson Study Group. Entacapone improves motor fluctuations in levodopatreated Parkinson's disease patients. Ann Neurol. 1997;42(5):747-755.
12. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibitionwith tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry. 1997;63(4):421-428.
13. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM; Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord. 2004;19(4):426-432. (Pubitemid 38559645)
14. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62(2):241-248.
15. Lang AE. Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: controversies and new approaches. Can J Neurol Sci. 1984;11(1)(suppl):210-220. (Pubitemid 14133470)
16. Goetz CG, Koller WC, Poewe W, Rascol O, Sampaio C. Management of Parkinson's disease: an evidence based review: amantadine and other antiglutamate agents. Mov Disord. 2002;17(Suppl 4):S13-S22.
17. Wolf E, Seppi K, Katzenschlager R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord. 2010;25(10):1357- 1363.
18. Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord. 2008;23(Suppl 3):S580-S584.
19. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005;20(5):523-539. (Pubitemid 40862249)
20. Fox SH, Katzenschlager R, Lim S-Y, et al. Treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011;26(suppl 3):S2-S41.
21. Pahwa R, Factor SA, Lyons KE, et al Quality Standards Subcommittee of the American Academy of Neurology. Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983-995. (Pubitemid 44044780)
22. Giladi N. Medical treatment of freezing of gait. Mov Disord. 2008;23(suppl 2):S482-S488.
23. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol. 2000;47(4)(suppl 1):S22-S32.
24. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg. 1992;76(1):53-61.
25. Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol. 2009;8(1):67-81.
26. Volkmann J, Sturm V, Weiss P, et al. Bilateral high-frequency stimulation of the internal globus pallidus in advanced Parkinson's disease. Ann Neurol. 1998;44(6):953-961. (Pubitemid 28558258)
27. Ponce FA, Lozano AM. Deep brain stimulation state of the art and novel stimulation targets. Prog Brain Res. 2010;184:311-324.
28. Deniau J-M, Degos B, Bosch C, Maurice N. Deep brain stimulation mechanisms: beyond the concept of local functional inhibition. Eur J Neurosci. 2010;32(7):1080-1091.
29. Hilker R, Portman AT, Voges J, et al. Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry. 2005;76(9):1217-1221. (Pubitemid 41208371)
30. Koller W, Pahwa R, Busenbark K, et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol. 1997;42(3):292-299. (Pubitemid 27391111)
31. Pahwa R, Lyons KE, Wilkinson SB, et al. Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg. 2006;104(4):506-512.
32. Tarsy D, Scollins L, Corapi K, O'Herron S, Apetauerova D, Norregaard T. Progression of Parkinson's disease following thalamic deep brain stimulation for tremor. Stereotact Funct Neurosurg. 2005;83(5-6):222-227.
33. Schuurman PR, Bosch DA, Merkus MP, Speelman JD. Long-term follow-up of thalamic stimulation versus thalamotomy for tremor suppression. Mov Disord. 2008;23(8):1146-1153.
34. HarizMI, Krack P, Alesch F, et al. Multicentre European study of thalamic stimulation for parkinsonian tremor: a 6 year follow-up. J Neurol Neurosurg Psychiatry. 2008;79(6):694-699. (Pubitemid 351829444)
35. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 1990;249(4975):1436-1438.
36. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 2003;349(20):1925-1934. (Pubitemid 37409709)
37. Schüpbach WMM, Chastan N, Welter ML, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry. 2005;76(12):1640-1644. (Pubitemid 41697626)
38. Piboolnurak P, Lang AE, Lozano AM, et al. Levodopa response in long-term bilateral subthalamic stimulation for Parkinson disease. Mov Disord. 2007;22(7):990-997. (Pubitemid 46999296)
39. Wider C, Pollo C, Bloch J, Burkhard PR, Vingerhoets FJG. Long-term outcome of 50 consecutive Parkinson's disease patients treated with subthalamic deep brain stimulation. Parkinsonism Relat Disord. 2008;14(2):114-119. (Pubitemid 351735982)
40. Gervais-Bernard H, Xie-Brustolin J, Mertens P, et al. Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: five year follow-up. J Neurol. 2009;256(2):225-233.
41. Simonin C, Tir M, Devos D, et al. Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon. J Neurol. 2009;256(10):1736-1741.
42. Romito LM, Contarino MF, Vanacore N, Bentivoglio AR, Scerrati M, Albanese A. Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: long-term observation. Mov Disord. 2009;24(4):557-563.
43. Kishore A, Rao R, Krishnan S, et al. Long-term stability of effects of subthalamic stimulation in Parkinson's disease: Indian experience. Mov Disord. 2010;25(14):2438-2444.
44. Deuschl G, Schade-Brittinger C, Krack P, et al German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896-908. (Pubitemid 44315982)
45. Weaver FM, Follett K, Stern M, et al CSP 468 Study Group. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63-73.
46. Williams A, Gill S, Varma T, et al; PD SURG Collaborative Group. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol. 2010;9(6):581-591.
47. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG,Weiner WJ. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol. 2010;67(1):64-70.
48. Weaver F, Follett K, Hur K, Ippolito D, Stern M. Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. J Neurosurg. 2005;103(6):956-967. (Pubitemid 43194543)
49. Ghika J, Villemure J-G, Fankhauser H, Favre J, Assal G, Ghika-Schmid F. Efficiency and safety of bilateral contemporaneous pallidal stimulation (deep brain stimulation) in levodopa-responsive patients with Parkinson's disease with severe motor fluctuations: a 2-year follow-up review. J Neurosurg. 1998;89(5):713-718. (Pubitemid 28485528)
50. Durif F, Lemaire J-J, Debilly B, Dordain G. Long-term follow-up of globus pallidus chronic stimulation in advanced Parkinson's disease. Mov Disord. 2002;17(4):803-807. (Pubitemid 41295029)
51. Lyons KE, Wilkinson SB, Tröster AI, Pahwa R. Long-term efficacy of globus pallidus stimulation for the treatment of Parkinson's disease. Stereotact Funct Neurosurg. 2002;79(3-4):214-220. (Pubitemid 36928771)
52. Volkmann J, Allert N, Voges J, Sturm V, Schnitzler A, Freund H-J. Long-term results of bilateral pallidal stimulation in Parkinson's disease. Ann Neurol. 2004;55(6):871-875. (Pubitemid 38702583)
53. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain. 2005;128(pt 10):2240-2249. (Pubitemid 41407964)
54. Follett KA, Weaver FM, Stern M, et al CSP 468 Study Group. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med. 2010;362(22):2077-2091.
55. Haberler C, Alesch F, Mazal PR, et al. No tissue damage by chronic deep brain stimulation in Parkinson's disease. Ann Neurol. 2000;48(3):372-376.
56. Videnovic A,Metman LV. Deep brain stimulation for Parkinson's disease: prevalence of adverse events and need for standardized reporting. Mov Disord. 2008;23(3):343-349.
57. Oh MY, Abosch A, Kim SH, Lang AE, Lozano AM. Long-term hardware-related complications of deep brain stimulation. Neurosurgery. 2002;50(6):1268-1274.
58. Lyons KE, Wilkinson SB, Overman J, Pahwa R. Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures. Neurology. 2004;63(4):612-616. (Pubitemid 39100813)
59. Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011;68(2):165-171.
60. Parsons TD, Rogers SA, Braaten AJ, Woods SP, Troster AI. Cognitive sequelae of subthalamic stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol. 2006;5(7):578-588. (Pubitemid 43867425)
61. Schroeder U, Kuehler A, Lange KW, et al. Subthalamic nucleus stimulation affects a frontotemporal network: a PET study. Ann Neurol. 2003;54(4):445-450. (Pubitemid 37176538)
62. Mikos A, Bowers D, Noecker AM, et al. Patient-specific analysis of the relationship between the volume of tissue activated during DBS and verbal fluency. Neuroimage. 2011;54(suppl 1):S238-S246.
63. Okun MS, Fernandez HH, Wu SS, et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol. 2009;65(5):586-595.
64. Saint-Cyr JA, Trépanier LL, Kumar R, Lozano AM, Lang AE. Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. Brain. 2000;123(pt 10):2091-2108.
65. Smeding HMM, Speelman JD, Huizenga HM, Schuurman PR, Schmand B. Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson's disease. J Neurol Neurosurg Psychiatry 2011;82(7):754-760. in Parkinson disease. Neurology. 2006;66(12):1830-1836.
66. Voon V, Kubu C, Krack P, Houeto J-L, Tröster AI. Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord. 2006;21(suppl 14):S305-S327. (Pubitemid 44028289)
67. Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol. 2008;7(7):605-614.
68. Temel Y, Kessels A, Tan S, Topdag A, Boon P, Visser-Vandewalle V. Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: a systematic review. Parkinsonism Relat Disord. 2006;12(5):265-272. (Pubitemid 43816341)
69. Kirsch-Darrow L, Mikos A, Bowers D. Does deep brain stimulation induce apathy in Parkinson's disease? Front Biosci. May 1, 2008;13:5316-5322.
70. Tröster AI. Short-term cognitive and affective outcomes after subthalamic deep brain stimulation for Parkinson's disease. Lancet Neurol. 2008;7(7):565-567.
71. Bejjani B-P, Damier P, Arnulf I, et al. Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med. 1999;340(19):1476-1480. (Pubitemid 29220547)
72. Kulisevsky J, Berthier ML, Gironell A, Pascual-Sedano B, Molet J, Parés P. Mania following deep brain stimulation for Parkinson's disease. Neurology. 2002;59(9):1421-1424. (Pubitemid 35285998)
73. Bejjani B-P, Houeto JL, Hariz M, et al. Aggressive behavior induced by intraoperative stimulation in the triangle of Sano. Neurology. 2002;59(9):1425-1427. (Pubitemid 35285999)
74. Romito LM, RajaM, Daniele A, et al. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord. 2002;17(6):1371-1374. (Pubitemid 36041360)
75. Burkhard PR, Vingerhoets FJG, Berney A, Bogousslavsky J, Villemure J-G, Ghika J. Suicide after successful deep brain stimulation for movement disorders. Neurology. 2004;63(11):2170-2172. (Pubitemid 39636276)
76. Appleby BS, Duggan PS, Regenberg A, Rabins PV. Psychiatric and neuropsychiatric adverse events associated with deep brain stimulation: a meta-analysis of ten years' experience. Mov Disord. 2007;22(12):1722-1728. (Pubitemid 47597595)
77. Voon V, Krack P, Lang AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain. 2008;131(pt 10):2720-2728.
78. Shih LC, Tarsy D. Deep brain stimulation for the treatment of atypical parkinsonism. Mov Disord. 2007;22(15):2149-2155.
79. Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. Neurology. 2001;57(4):663-671. (Pubitemid 32782995)
80. Meissner W, Schreiter D, Volkmann J, et al. Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany. J Neurol. 2005;252(2):218-223. (Pubitemid 40385598)
81. Charles PD, Padaliya BB, Newman WJ, et al. Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. Parkinsonism Relat Disord. 2004;10(8):475-479. (Pubitemid 39489880)
82. Fraix V, Houeto J-L, Lagrange C, et al SPARK Study Group. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2006;77(4):443-449.
83. Valldeoriola F, Morsi O, Tolosa E, Rumià J, Martí MJ, Martínez-Martín P. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease. Mov Disord. 2007;22(15):2183-2191.
84. Welter ML, Houeto J-L, Tezenas du Montcel S, et al. Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain. 2002;125(Pt 3):575-583. (Pubitemid 34194412)
85. Siderowf A, Jaggi JL, Xie SX, et al. Long-term effects of bilateral subthalamic nucleus stimulation on health-related quality of life in advanced Parkinson's disease. Mov Disord. 2006;21(6):746-753. (Pubitemid 44028291)
86. Volkmann J, Albanese A, Kulisevsky J, et al. Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease. Mov Disord. 2009;24(8):1154-1161.